Caspofungin Acetate Patent Expiration
Caspofungin Acetate was first introduced by Merck And Co Inc
Caspofungin Acetate Patents
Given below is the list of patents protecting Caspofungin Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Caspofungin Acetate | US9636407 | Caspofungin acetate formulations | Dec 21, 2032 | Fresenius Kabi Usa |
| Cancidas |
US5952300 (Pediatric) | Antifungal compositions |
Sep 28, 2017
(Expired) | Merck |
| Cancidas |
US6136783 (Pediatric) | Antifungal compositions |
Sep 28, 2017
(Expired) | Merck |
| Cancidas | US5952300 | Antifungal compositions |
Mar 28, 2017
(Expired) | Merck |
| Cancidas | US6136783 | Antifungal compositions |
Mar 28, 2017
(Expired) | Merck |
| Cancidas |
US5514650 (Pediatric) | Aza cyclohexapeptide compounds |
Jul 26, 2015
(Expired) | Merck |
| Cancidas | US5514650 | Aza cyclohexapeptide compounds |
Jan 26, 2015
(Expired) | Merck |
| Cancidas |
US5378804 (Pediatric) | Aza cyclohexapeptide compounds |
Sep 16, 2013
(Expired) | Merck |
| Cancidas |
US5792746 (Pediatric) | Aza cyclohexapeptide compounds |
Sep 16, 2013
(Expired) | Merck |
| Cancidas | US5378804 | Aza cyclohexapeptide compounds |
Mar 16, 2013
(Expired) | Merck |
| Cancidas | US5792746 | Aza cyclohexapeptide compounds |
Mar 16, 2013
(Expired) | Merck |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Caspofungin Acetate's patents.
Latest Legal Activities on Caspofungin Acetate's Patents
Given below is the list recent legal activities going on the following patents of Caspofungin Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Nov, 2020 | US9636407 |
| Recordation of Patent Grant Mailed Critical | 02 May, 2017 | US9636407 |
| Patent Issue Date Used in PTA Calculation Critical | 02 May, 2017 | US9636407 |
| Email Notification Critical | 13 Apr, 2017 | US9636407 |
| Issue Notification Mailed Critical | 12 Apr, 2017 | US9636407 |
| Dispatch to FDC | 29 Mar, 2017 | US9636407 |
| Application Is Considered Ready for Issue Critical | 28 Mar, 2017 | US9636407 |
| Issue Fee Payment Verified Critical | 27 Mar, 2017 | US9636407 |
| Issue Fee Payment Received Critical | 27 Mar, 2017 | US9636407 |
| Mail PUBS Letter Withdrawing a Notice Requiring Inventors Oath or Declaration | 15 Mar, 2017 | US9636407 |
Caspofungin Acetate's Family Patents
Explore Our Curated Drug Screens
Caspofungin Acetate Generic API Manufacturers
Several generic applications have been filed for Caspofungin Acetate. The first generic version for Caspofungin Acetate was by Gland Pharma Ltd and was approved on Sep 29, 2017. And the latest generic version is by Areva Pharmaceuticals Inc and was approved on Oct 1, 2021.
Given below is the list of companies who have filed for Caspofungin Acetate generic, along with the locations of their manufacturing plants worldwide.
1. AREVA PHARMS
Areva Pharmaceuticals Inc has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Areva Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/VIAL | powder | Prescription | INTRAVENOUS | AP | Oct 1, 2021 |
| 70MG/VIAL | powder | Prescription | INTRAVENOUS | AP | Oct 1, 2021 |
2. CIPLA
Cipla Ltd has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Jul 12, 2018 |
| 70MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Jul 12, 2018 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
3. GLAND
Gland Pharma Ltd has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Gland.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/VIAL | powder | Prescription | INTRAVENOUS | AP | Sep 29, 2017 |
| 70MG/VIAL | powder | Prescription | INTRAVENOUS | AP | Sep 29, 2017 |
Manufacturing Plant Locations New
Gland's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Gland as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
4. HENGRUI PHARMA
Jiangsu Hengrui Pharmaceuticals Co Ltd has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Hengrui Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/VIAL
(reference standard) | powder | Prescription | INTRAVENOUS | AP | Jun 28, 2018 |
| 70MG/VIAL
(reference standard) | powder | Prescription | INTRAVENOUS | AP | Jun 28, 2018 |
5. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Sep 29, 2017 |
| 70MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Sep 29, 2017 |
6. XELLIA PHARMS APS
Xellia Pharmaceuticals Aps has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Xellia Pharms Aps.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 70MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Jul 2, 2018 |
| 50MG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Jul 2, 2018 |